Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10683371rdf:typepubmed:Citationlld:pubmed
pubmed-article:10683371lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C0796520lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C1513792lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C0041485lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C1302234lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:10683371lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:10683371pubmed:issue4lld:pubmed
pubmed-article:10683371pubmed:dateCreated2000-3-9lld:pubmed
pubmed-article:10683371pubmed:abstractTextThe t(5;12)(q33;p13) translocation associated with chronic myelomonocytic leukemia (CMML) generates a TEL/PDGFbetaR fusion gene. Here, we used a murine bone marrow transplant (BMT) assay to test the transforming properties of TEL/PDGFbetaR in vivo. TEL/PDGFbetaR, introduced into whole bone marrow by retroviral transduction, caused a rapidly fatal myeloproliferative disease that closely recapitulated human CMML. TEL/PDGFbetaR transplanted mice developed leukocytosis with Gr-1(+) granulocytes, splenomegaly, evidence of extramedullary hematopoiesis, and bone marrow fibrosis, but no lymphoproliferative disease. We assayed mutant forms of the TEL/PDGFbetaR fusion protein - including 8 tyrosine to phenylalanine substitutions at phosphorylated PDGFbetaR sites to which various SH2 domain-containing signaling intermediates bind - for ability to transform hematopoietic cells. All of the phenylalanine (F-) mutants tested conferred IL-3-independence to a cultured murine hematopoietic cell line, but, in the BMT assay, different F-mutants displayed distinct transforming properties. In transplanted animals, tyrosines 579/581 proved critical for the development of myeloproliferative phenotype. F-mutants with these residues mutated showed no sign of myeloproliferation but instead developed T-cell lymphomas. In summary, TEL/PDGFbetaR is necessary and sufficient to induce a myeloproliferative disease in a murine BMT model, and PDGFbetaR residues Y579/581 are required for this phenotype.lld:pubmed
pubmed-article:10683371pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:languageenglld:pubmed
pubmed-article:10683371pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10683371pubmed:statusMEDLINElld:pubmed
pubmed-article:10683371pubmed:monthFeblld:pubmed
pubmed-article:10683371pubmed:issn0021-9738lld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:CarrollMMlld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:WilliamsI RIRlld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:GillilandD...lld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:AsterJ CJClld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:CajaRRlld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:Van EttenR...lld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:SternbergD...lld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:IlariaR LRLJrlld:pubmed
pubmed-article:10683371pubmed:authorpubmed-author:TomassonM HMHlld:pubmed
pubmed-article:10683371pubmed:issnTypePrintlld:pubmed
pubmed-article:10683371pubmed:volume105lld:pubmed
pubmed-article:10683371pubmed:ownerNLMlld:pubmed
pubmed-article:10683371pubmed:authorsCompleteYlld:pubmed
pubmed-article:10683371pubmed:pagination423-32lld:pubmed
pubmed-article:10683371pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:meshHeadingpubmed-meshheading:10683371...lld:pubmed
pubmed-article:10683371pubmed:year2000lld:pubmed
pubmed-article:10683371pubmed:articleTitleFatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.lld:pubmed
pubmed-article:10683371pubmed:affiliationDepartment of Medicine, Brigham and Women's Hospital, Harvard Institutes of Medicine, Boston, Massachusetts 02115, USA.lld:pubmed
pubmed-article:10683371pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10683371pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10683371pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed